60336-41-6

Usage

Chemical composition

Consists of a phenyl group with a chlorine substituent and an N-methylacetamide group.

Physical form

White to off-white crystalline solid.

Usage

Served as a pharmaceutical intermediate in the synthesis of various drugs.

Potential properties

Found to have potential analgesic and anti-inflammatory properties, making it a candidate for the development of new pain-relieving medications.

Utility

Structure and properties make it a useful building block in the production of other organic compounds.

Precautions

May pose hazards to human health and the environment if not properly managed.

Upstream product

• 25026-34-0 4-chlorophenacetyl chloride 
• 74-89-5 methylamine 
• 1878-66-6 4-chlorophenylacetic Acid 
• 52449-43-1 (4-chloro-phenyl)-acetic acid methyl ester 
• 96-31-1 N,N'-Dimethylurea 

Downstream Products

• 38171-31-2 N-methyl-2-(4-chlorophenyl)ethylamine 
• 877265-15-1 7-chloro-2-methyl-1,4-dihydro-2H-isoquinolin-3-one 
• 87292-81-7 3-chloro-4-(4-chlorophenyl)-1-methyl-1H-pyrrole-2,5-dione 

Relevant academic research and scientific papers

Direct synthesis of amides from nonactivated carboxylic acids using urea as nitrogen source and Mg(NO3)2or imidazole as catalysts

A new method for the direct synthesis of primary and secondary amides from carboxylic acids is described using Mg(NO3)2·6H2O or imidazole as a low-cost and readily available catalyst, and urea as a stable, and easy to manipulate nitrogen source. This methodology is particularly useful for the direct synthesis of primary and methyl amides avoiding the use of ammonia and methylamine gas which can be tedious to manipulate. Furthermore, the transformation does not require the employment of coupling or activating agents which are commonly required.

Synthesis of aryl anilinomaleimide based derivatives as glycogen synthase kinase-3β inhibitors with potential role as antidepressant agents

A series of aryl anilinomaleimide based derivatives has been synthesized and evaluated for in vitro glycogen synthase kinase-3β (GSK-3β) inhibitory activity. A large number of compounds from the series exhibited moderate to potent inhibitory activity against GSK-3β, with more than one-third of the compounds showing inhibition with IC50 values 50 values of 0.09, 0.12, 0.17, 0.19, 0.21 and 0.23 μM respectively), were further investigated for antidepressant activity by the widely accepted forced swim test and tail suspension test (FST and TST) models. All the tested compounds displayed antidepressant-like effects, particularly compounds 8j and 8b, which exhibited significant antidepressant activity, about 1.4-fold higher than fluoxetine, a standard antidepressant drug in both FST and TST. Preliminary structure-activity relationships have also been generated based on the experimental data obtained.

Process development and pilot-scale synthesis of new cyclization conditions of substituted phenylacetamides to tetrahydroisoquinoline-2-ones using Eaton's reagent

Tetrahydroisoquinoline is a ubiquitous structural framework presented in numerous pharmacologically relevant molecules. Although accessible by the Pictet-Spengler cyclization, conditions commonly used for such cyclizations are often difficult to implement on scale. Herein, we report the development of a scaleable approach utilizing Eaton's reagent for the cyclization of substituted phenylacetamide analogues to tetrahydroisoquinoline-2-one. The development, optimization, and safety hazard evaluations, which outline the benefits and ease of workup of this new process, are discussed.